Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer

By Sørbye Halfdan   Berglund Åke   Tveit Kjell Magne   Øgreid Dagfinn   Wanderås Eva Hoff   Wentzel-Larsen Tore   Dahl Olav   Glimelius Bengt  

Acta Oncologica, Vol. 46, Iss. 7, 2007-01 ,pp. : 982-988

Informa Healthcare

Access to resources Recommend Favorite

Oxaliplatin/cisplatin (L-OHP/CDDP) Combination in Heavily Pretreated Ovarian Cancer

By Soulie P.   Bensmaine A.   Garrino C.   Chollet P.   Brain E.   Fereres M.   Jasmin C.   Musset M.   Misset J.L.   Cvitkovic E.  

European Journal of Cancer, Vol. 33, Iss. 9, 1997-08 ,pp. : 1400-1406

Elsevier

Access to resources Recommend Favorite

Comparison of the combined action of oxaliplatin or cisplatin and radiation in cervical and lung cancer cells

By Rave-Fränk Margret   Schmidberger Heinz   Christiansen Hans   Boll Christine   Lehmann Jörg   Weiss Elisabeth  

International Journal of Radiation Biology, Vol. 83, Iss. 1, 2007-01 ,pp. : 41-47

Informa Healthcare

Access to resources Recommend Favorite

Phase I study of gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer

By Caffo O.   Fellin G.   Graffer U.   Valduga F.   Bolner A.   Luciani L.   Tomio L.   Galligioni E.  

International Journal of Radiation Oncology*Biology*Physics, Vol. 57, Iss. 5, 2003-12 ,pp. : 1310-1316

Elsevier

Access to resources Recommend Favorite

Chemotherapy with Doxorubicin, Etoposide and Cyclophosphamide (DEC) in Ovarian Cancer Persistent after Platinum-based Treatment

By Zanetta G.   Monico S.L.   Gabriele A.   Miceli D.   Mangioni C.  

European Journal of Cancer, Vol. 32, Iss. 1, 1996-01 ,pp. : 178-179

Elsevier

Access to resources Recommend Favorite